Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Memorial Sloan-Kettering Cancer Center, New York

Wihship Cancer Institute of Emory University, Atlanta

University of Michigan Comprehensive Cancer Center, Ann Arbor

Mayo Clinic, Rochester

Oklahoma University Health Sciences Center, Oklahoma City

The University of Texas MD Anderson Cancer Center, Houston

University of California, Los Angeles, Los Angeles

Dana-Farber Cancer Institute, Boston

Fox Chase Cancer Center, Philadelphia

University Hospital Antwerp, Antwerp

Cliniques universitaires Saint-Luc, Brussels

CHU, Yvoir

Insitut Bergonie, Bordeaux

Centre Léon Bérard, Lyon

Centre Antoine Lacassagne, Nice

Institute Gustave Roussy (IGR), Paris

University Hospital Wuerazburg, Würzburg

Attikon University Hospital, Attiki

Instituto Nazionale Tumori, Milan

University Medical Center, Groningen

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Hospital Clinic de Barcelona, Barcelona

Hospital del Mar, Barcelona

Hospital Universitario Doce de Octubre, Madrid

Hospital Universitario La Paz, Madrid

MD Anderson Cancer Center Madrid, Madrid

START, Centro Integral Oncologico Clara Campal, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Complejo Hospitalario de Navarro, Navarro

Hospital Universitario Virgen de la Rocio, Seville

Hospital Universitario y Politécnico La Fe, Valencia

Royal Marsden, London

University College Hospital, London

Hospital Vall d' Hebron, Barcelona